Cardio Diagnostics Holdings, Inc. announced its financial results for the first quarter of 2025, reporting a net loss of US$1.64 million. This figure reflects the company's continued investment in its AI-driven precision cardiovascular medicine platform.
The company's Earnings Per Share (EPS) reportedly beat expectations, but revenues lagged behind projections for the quarter. This indicates that while cost management may be improving, top-line growth remains a challenge.
The ongoing net loss underscores the company's current unprofitability and its reliance on external funding to support operations and growth initiatives. Investors will continue to monitor revenue trends and expense management in future reports.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.